Urolithiasis in Primary Gout, Incidence of Clinically Presented and Asymptomatic Kidney Stones: Identification of Significant Risk Factors
DOI:
https://doi.org/10.17140/UAOJ-7-143Keywords:
Spontaneous, Bladder, Rupture, Atraumatic, Urine extravasationAbstract
Background
The aim of this study is to explore the prevalence of urolithiasis in patients with primary gout as well as its correlation with other associated risk factors.
Methods
The study was conducted on 102 patients with primary gout, they underwent ultrasonography examination and their general, clinical, and urinalysis data were recorded for further assessment and statistical analysis.
Results
There were 102 patients with primary gout included in our study, 69 (67.6%) males, mean age of patients was 64.3±9.7. The overall
prevalence of urolithiasis in our patients with primary gout is 37.3% and 15.7% have “silent” urolithiasis. Patients with urolithiasis
(Group 1) are significantly older, 68.9±7.4-years, had a long history of gout 10.3±4.5-years, presence of tophi in 9 (23.6%) patients
and more than 3 gouty arthritis attacks per year in 17(44.7%) patients. Also, patients in Group 1 have a significantly lower urine
pH of 5.2±0.4 compared to patients without urolithiasis (Group 2) who have a urine pH of 6.6±0.2. Results showed that obesity,
diabetes, and hyperlipidemia are significantly more common in patients with urolithiasis (Group 1) while the presence of hyper
tension is not significantly different between groups. Correlation between urolithiasis and parameters related to disease (duration,
tophi, and more than three attacks per year) and parameters related to urinalysis (pH and crystalluria) was tested and found statistically significant. Logistic regression analyses (univariate and multivariate) of tested parameters confirmed that obesity, diabetes
mellitus, and hyperlipidemia are predictive factors for the presence of urolithiasis in patients with primary gout.
Conclusion
There is a high prevalence of urolithiasis in patients with primary gout including asymptomatic urolithiasis, associated with the age
of patients, duration, and severity of gout, obesity, diabetes, and hyperlipidemia. Therefore, ultrasonographic screening as harmless and available should be recommended in order to prevent complications.
References
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020; 50(3S): S11-S16. doi: 10.1016/j. semarthrit.2020.04.008
Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The health professionals’ Follow-Up Study. Kidney Int. 2003; 64(3): 1022-1026. doi: 10.1046/j.1523-1755.2003.t01-2-00171.x
Richette P, Bardin T. Gout. Lancet. 2010; 375 (9711): 318-328. doi: 10.1016/S0140-6736(09)60883-7
Shimizu T, Hori H. The prevalence of nephrolithiasis in patients with primary gout: A cross-sectional study using helical computed tomography. J Rheumatol. 2009; 36(9): 1958-1962. doi: 10.3899/ jrheum.081128
Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: Is a reappraisal needed? J Rheumatol. 2005; 32(11): 2189-2191.
Radosavljević Z, Milenković D, Radosavljević N. Učestalost urolitijaze kod pacijenata sa gihtom [In: Croatian]. Acta Rheumatologica Belgradensia. 2009; 39(1): 96.
Radosavljevic Z, Milenkovc D, Radosavljevic N. Frequency of urolithiasis in primary gout. Eur Urol Suppl. 2009; 8(8): 645. doi: 10.1016/S1569-9056(09)74995-4
Radosavljevic Z, Savic S, Savic N, Radosavljevic N. Primary gout as a risk factor for urolithiasis. Eur Urol Suppl. 2011; 10(9): 589. doi: 10.1016/S1569-9056(11)61494-2
Lallas CD, Liu XS, Chiura AN, Das AK, Bagley DH. Urolithiasis location and size and the association with microhematuria and stone-related symptoms. J Endourol. 2011; 25(12): 1909-1913. doi:
1089/end.2011.0265 10. Ulusan S, Koc Z, Tokmak N. Accuracy of sonography for detecting renal stone: Comparison with CT. J Clin Ultrasound. 2007; 35(5): 256-261. doi: 10.1002/jcu.20347
Stansbridge EM, Griffin DG, Walker V. Who makes uric acid stones and why--observations from a renal stones clinic. J Clin Pathol. 2013; 66(5): 426-431. doi: 10.1136/jclinpath-2012-201373
Walker V, Stansbridge EM, Griffin DG. Demography and biochemistry of 2800 patients from a renal stones clinic. Ann Clin Biochem. 2013; 50(Pt 2): 127-139. doi: 10.1258/acb.2012.012122
Kramer HM, Curhan G. The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002; 40: 37-42. doi: 10.1053/ajkd.2002.33911
Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2012; 63(4): 238-245. doi: 10.4081/reumatismo.2011.238
Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes. 2012; 10: 117. doi: 10.1186/1477-7525-10-117
Bakris GL, Doghramji PP, Keenan RT, Silber SH. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med. 2014; 127(1): S1. doi: 10.1016/j.amjmed.2013.11.001
Kang DH, Nakagawa T. Uric acid and chronic renal disease: Submit your article to this journal | https://openventio.org/submit-manuscript/ possible implication of hyperuricemia on progression of renal disease. Semin Nephrol. 2005; 25: 43-49. doi: 10.1016/j. semnephrol.2004.10.001
Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol. 2014; 27(3): 241-245. doi: 10.1007/ s40620-013-0034-z
Bell DS. Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes. Diabetes Obes Metab. 2012; 14(4): 299-303. doi: 10.1111/j.1463-1326.2011.01519.x
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007; 57: 109-115. doi: 10.1002/art.22466
Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008; 47: 1567-1570. doi: 10.1093/ rheumatology/ken305
Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005; 165: 742-748. doi: 10.1001/archinte.165.7.742
Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens. 2008; 17(3): 304-309. doi: 10.1097/ MNH.0b013e3282f8b34d
Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: A Systemic Metabolic disorder. Clin Rev Bone Miner Metab. 2011; 9(3-4): 207- 217. doi: 10.1007/s12018-011-9106-6
Shavit L, Ferraro PM, Johri N, et al. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transplant. 2015; 30(4): 607-613. doi: 10.1093/ndt/ gfu350
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Urology and Andrology (UA) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
